Health care and data analysts examining the international liver disease landscape predict that the global market for lifesaving treatments will expand significantly by 2020. According to a recent report from Persistence Market Research, North America currently has the largest demand for cures, prevention and medicine, followed by Europe and Asia. 

The global market for liver disease treatment is categorized based on various drug types (e.g, vaccines, antivirals, corticosteroids, anti-rejection drugs) and by type of illness (viral hepatitis, autoimmune diseases, cancers, non-alcoholic fatty liver disease and more). Researchers say that in 2018, the antiviral drug market represents the largest sub-segment in the current global market, and hepatitis treatment remains the largest and fastest-growing sub-segment for treatment.

Within North America, which has the largest market for liver disease treatment, the United States has the highest demand, while in Europe, Germany, France and the United Kingdom cover the major share of the liver disease treatment market. Asia is currently the fastest-growing market for new hepatitis and liver disease drugs, largely due to an increase in geriatric patients. 

Key companies operating in the liver disease treatment market include Abbott Laboratories, Actavis, Aton Pharma, Bayer Schering AG, Biotest, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, GlaxoSmithkline, Gilead Sciences, Merck & Co., Mylan, Novartis, Pfizer, Roche and Takeda Pharmaceuticals. 

Experts say aging populations, alcohol consumption and the growing prevalence of liver diseases around the world are largely driving the market. Additionally, high unmet needs for the treatment of liver cancer contribute to the growing liver disease treatment market, all of which indicates that the market has no indications of slowing.